Relmacabtagene autoleucel - JW Therapeutics
Alternative Names: Carteyva; JWCAR-029; relma-celLatest Information Update: 28 May 2025
At a glance
- Originator Juno Therapeutics
- Developer JW Therapeutics; Shanghai Ming Ju Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Preregistration Diffuse large B cell lymphoma
- Phase I Chronic lymphocytic leukaemia; Systemic lupus erythematosus
- No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, Second-line therapy or greater, In adults) in China (IV)
- 10 Jan 2025 Ming Ju Biotechnology initiates a phase II trial for Non-Hodgkin's lymphoma (Second line therapy or greater) in China (IV) (NCT06093841)
- 10 Jan 2025 Relmacabtagene autoleucel - JW Therapeutics receives Breakthrough Therapy status for B-cell lymphoma (Second-line therapy or greater, In adults) in China